5-ethyl-nicotinamide | 1585182-38-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 5-ethyl-nicotinamide
• 英文别名: 5-Ethylpyridine-3-carboxamide
• CAS: 1585182-38-2
• 化学式: C₈H₁₀N₂O
• 分子量: 150.18
• InChiKey: RZCPLSWWQYBTTP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.5
• 重原子数：
  11
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  56
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2,3,5-tri-O-benzoyl-β-D-ribofuranosyl bromide 、 5-ethyl-nicotinamide 以 乙腈 为溶剂， 反应 48.0h， 以270 mg的产率得到N’-(2,3,5-tri-o-benzoyl-β-D-ribofuranosyl)-3-aminocarbonyl-5-ethyl-pyridinium bromide
  参考文献：
  名称：

  Engineering the Substrate Specificity of ADP-Ribosyltransferases for Identifying Direct Protein Targets

  摘要：

  Adenosine diphosphate ribosyltransferases (ARTDs; ARTD1-17 in humans) are emerging as critical regulators of cell function in both normal physiology and disease. These enzymes transfer the ADP-ribose moiety from its substrate, nicotinamide adenine dinucleotide (NAD(+)), to amino acids of target proteins. The functional redundancy and overlapping target specificities among the 17 ARTDs in humans make the identification of direct targets of individual ARTD family members in a cellular context a formidable challenge. Here we describe the rational design of orthogonal NAD(+) analogue-engineered ARTD pairs for the identification of direct protein targets of individual ARTDs. Guided by initial inhibitor studies with nicotinamide analogues containing substituents at the C-5 position, we synthesized an orthogonal NAD(+) variant and found that it is used as a substrate for several engineered ARTDs (ARTD1, -2, and -6) but not their wild-type counterparts. Comparing the target profiles of ARTD1 (PARP1) and ARTD2 (PARP2) in nuclear extracts highlighted the semi-complementary, yet distinct, protein targeting. Using affinity purification followed by tandem mass spectrometry, we identified 42 direct ARTD1 targets and 301 direct ARTD2 targets. This represents a powerful new technique for identifying direct protein targets of individual ARTD family members, which will facilitate studies delineating the pathway from ARTD activation to a given cellular response.

  DOI：

  10.1021/ja412897a
• 作为产物：
  描述：

  5-vinyl-nicotinamide 在 palladium 10% on activated carbon 、 氢气 作用下， 以 甲醇 为溶剂， 反应 5.0h， 以91%的产率得到5-ethyl-nicotinamide
  参考文献：
  名称：

  Engineering the Substrate Specificity of ADP-Ribosyltransferases for Identifying Direct Protein Targets

  摘要：

  Adenosine diphosphate ribosyltransferases (ARTDs; ARTD1-17 in humans) are emerging as critical regulators of cell function in both normal physiology and disease. These enzymes transfer the ADP-ribose moiety from its substrate, nicotinamide adenine dinucleotide (NAD(+)), to amino acids of target proteins. The functional redundancy and overlapping target specificities among the 17 ARTDs in humans make the identification of direct targets of individual ARTD family members in a cellular context a formidable challenge. Here we describe the rational design of orthogonal NAD(+) analogue-engineered ARTD pairs for the identification of direct protein targets of individual ARTDs. Guided by initial inhibitor studies with nicotinamide analogues containing substituents at the C-5 position, we synthesized an orthogonal NAD(+) variant and found that it is used as a substrate for several engineered ARTDs (ARTD1, -2, and -6) but not their wild-type counterparts. Comparing the target profiles of ARTD1 (PARP1) and ARTD2 (PARP2) in nuclear extracts highlighted the semi-complementary, yet distinct, protein targeting. Using affinity purification followed by tandem mass spectrometry, we identified 42 direct ARTD1 targets and 301 direct ARTD2 targets. This represents a powerful new technique for identifying direct protein targets of individual ARTD family members, which will facilitate studies delineating the pathway from ARTD activation to a given cellular response.

  DOI：

  10.1021/ja412897a

文献信息

• [EN] COMPOUNDS AND METHODS FOR MODULATING ADENOSINE A2B RECEPTOR AND ADENOSINE A2A RECEPTOR<br/>[FR] COMPOSÉS ET PROCÉDÉS DE MODULATION DU RÉCEPTEUR A2B DE L'ADÉNOSINE ET DU RÉCEPTEUR A2A DE L'ADÉNOSINE
  申请人：CORVUS PHARMACEUTICALS INC

  公开号：WO2019046784A1

  公开（公告）日：2019-03-07

  Disclosed herein, inter alia, are compositions and methods for modulating Adenosine Receptors. In an aspect is provided a method of inhibiting Adenosine A2B Receptor activity and Adenosine A2A Receptor activity, the method including contacting the Adenosine A2B Receptor and Adenosine A2A Receptor with a compound as described herein, including embodiments.

  在此披露的内容包括调节腺苷受体的组合物和方法。在一个方面，提供了一种抑制腺苷A2B受体活性和腺苷A2A受体活性的方法，该方法包括将腺苷A2B受体和腺苷A2A受体与本文描述的化合物接触，包括各种实施方式。
• TRICYCLIC GYRASE INHIBITORS
  申请人：Bensen Daniel

  公开号：US20120238751A1

  公开（公告）日：2012-09-20

  Disclosed herein are compounds having the structure of Formula I and pharmaceutically suitable salts, esters, and prodrugs thereof that are useful as antibacterially effective tricyclic gyrase inhibitors. Related pharmaceutical compositions, uses and methods of making the compounds are also contemplated.

  本文披露了具有式I结构的化合物，以及作为抗菌有效的三环酶抑制剂的药用盐、酯和前药，相关的药物组合物、用途和制备该化合物的方法也在考虑之中。
• [EN] PYRAZOLE COMPOUNDS AS MODULATORS OF FSHR AND USES THEREOF<br/>[FR] COMPOSÉS DE PYRAZOLE UTILISÉS EN TANT QUE MODULATEURS DE FSHR ET LEURS UTILISATIONS
  申请人：TOCOPHERX INC

  公开号：WO2015196759A1

  公开（公告）日：2015-12-30

  Disclosed are pyrazole compounds, and pharmaceuticaly acceptable compositions thereof. The compounds and the compositions can be used for positive allosteric modulators of follicle stimulating hormone receptor (FSHR).

  揭示了吡唑化合物及其药用组合物。这些化合物和组合物可用作促卵泡激素受体（FSHR）的阳性变构调节剂。
• BENZAMIDE FACTOR VIIA INHIBITORS USEFUL AS ANTICOAGULANTS
  申请人：Priestley Eldon Scott

  公开号：US20100227894A1

  公开（公告）日：2010-09-09

  The present invention provides novel benzamide derivatives of Formula (I): or a stereoisomer, tautomer, pharmaceutically acceptable salt, solvate, or prodrug thereof, wherein the variables A, W, Y, Z, R 8 , and R 9 are as defined herein. These compounds are selective inhibitors of factor VIIa which can be used as medicaments.

  本发明提供了式(I)的新型苯甲酰胺衍生物：或其立体异构体、互变异构体、药学上可接受的盐、溶剂合物或前药，其中变量A、W、Y、Z、R8和R9如本文所定义。这些化合物是选择性因子VIIa的抑制剂，可用作药物。
• COMPOUNDS AND METHODS OF PREPARING COMPOUNDS S1P1 MODULATORS
  申请人：Trevena, Inc.

  公开号：US20210147402A1

  公开（公告）日：2021-05-20

  The present embodiments are directed, in part, to processes and compositions that can, for example, be used in the preparation compounds of Formula (I), or a pharmaceutically acceptable salts thereof.

  本实施例部分涉及可用于制备化合物I的过程和组合物，或其药用可接受的盐。